Amantadine has been shown to have antiviral activity prophylactically and therapeutically against influenza A infection (2, 7, 11, 16, 17) but has not been used widely by physicians. This may be due in part to concern regarding reported central nervous system side effects, such as inability to concentrate, insomnia, and nervousness, which are usually infrequent and minimal (3, 7, 10, 11) . Rimantadine, an analog of amantadine, has been shown to have similar antiviral efficacy but reportedly fewer side effects ( 483, 1978) . Recent studies suggest that amantadine has depressive effects on various psychomotor functions, such as the ability to sustain attention and the perception of spatial relationships (3, 12) . However, there are limitations in these studies, and the clinical significance of these findings has not been established. Some observers have suggested that, qualitatively, the side effects of amantadine are no more significant than those produced by antihistamine drugs which are well accepted by the public (10) . Since amantadine may have anticholinergic effects similar to those of antihistamines which are commonly used to treat the symptoms of influenza, concurrent use might potentiate side effects (4) .
To put the significance of these side effects into perspective, we compared the effects of amantadine, rimantadine, and a commonly used antihistamine (chlorpheniramine) on the central nervous system. Side effects studied included subjective complaints and performance on tests of attention, cognition, and memory, which were examined in a controlled, blind study in healthy adults.
MATERIALS AND METHODS
Between October 1979 and January 1980, 52 adult volunteers were recruited from the University of California at Los Angeles (UCLA) student population. The study group included an equal number of men and women whose ages ranged from 18 to 44 years, with a mean of 25 years. Volunteers with a history of seizures, renal disease, or pregnancy or those taking antihistamine drugs or other medications that might mimic or enhance the effects of the study drugs were excluded. Subjects were enrolled after informed consent was obtained.
Medications. Amantadine and rimantadine and their lactose placebo were identical, salmon-colored tablets provided by Endo Laboratories. An antihistamine, chlorpheniramine, and its lactose placebo were identical white tablets prepared by the UCLA Investigational Drug Unit.
Study group assignment. Subjects were randomized in a double-blind manner to drug or placebo groups as follows. The amantadine group was given amantadine (100 mg) and chlorpheniramine placebo every 12 h; the amantadine-chlorpheniramine group was given amantadine (100 mg) and chlorpheniramine (4 mg) every 12 h; the chlorpheniramine group was given chlorpheniramine (4 mg) and an antiviral placebo every 12 h; the rimantadine group was given rimantadine (100 mg) and chlorpheniramine placebo every 12 h; and the placebo group was given an antiviral placebo and a chlorpheniramine placebo every 12 h.
Ten subjects were enrolled in the amantadine, rimantadine, and placebo groups, and 11 subjects were enrolled in the amantadine-chlorpheniramine and chlorpheniramine groups. Subjects were instructed to take one salmon-colored and one white tablet between 8 and 9 a.m. and 8 and 9 p.m. daily for a period of 3 to 4 days, 1 h before or 2 h after meals. All subjects were Bryson et al. (2) used the same test battery as that used in the present study and reported depressed performance on the Critical Tracking Test and Children's Checking Test. The study had several limitations, however, due to the crossover design, with an imbalance of treatment sequence groups and a practice effect observed on the Critical Tracking Test. In the present study, this practice effect was abolished or minimized by multiple trials before testing. Our data is in agreement with a report by Hayden et al. (6) , who found that no significant effects of amantadine or rimantadine on psychomotor function occurred at a dosage of 200 mg, but that performance of attentional tasks was decreased when the dose was increased to 300 mg daily. We found that, although the combination of amantadine and chlorpheniramine enhanced The practical use of amantadine and rimantadine depends upon low toxicity and high efficacy in the treatment and prophylaxis of influenza A infection. Our data suggest that these antiviral agents have minimal side effects which are comparable to those of a common antihistamine and do not significantly affect higher central nervous system functions. However, physicians should be aware of the possibility of potentiation of side effects when amantadine and antihistamines are used in combination. 
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